

# ESMO Preceptorship on Non-Small-Cell Lung Cancer

## PROGRAMME

**ESMO  
PRECEPTORSHIP**

**HELSINKI FINLAND  
22-23 MAY 2024**

**Co-Chairs**

Pasi A. Jänne, United States  
Solange Peters, Switzerland

# ESMO PRECEPTORSHIP PROGRAMME NON-SMALL-CELL LUNG CANCER

Standards of care, evolving paradigm and future perspectives

Helsinki, Finland  
22-23 May 2024

---

## CO-CHAIRS

Pasi A. Jänne, United States  
Solange Peters, Switzerland

## SPEAKERS

Haseem Ashraf, Norway  
Odd Terje Brustugun, Norway  
Alessandra Curioni-Fontecedro, Switzerland  
Inger Johanne Zwicky Eide, Norway  
Enriqueta Felip, Spain  
Åslaug Helland, Norway  
Ilkka Ilonen, Finland

Keith M. Kerr, United Kingdom  
Karin Lindberg, Sweden  
Patrick Micke, Sweden  
Jan Nyman, Sweden  
Noemi Reguart, Spain  
Egbert F. Smit, The Netherlands  
Jens Benn Sørensen, Denmark

---

## LEARNING OBJECTIVES

- To learn about best clinical practice in the management of Non-Small-Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic setting
- To understand the importance of pathology, histo-prognostic and molecular factors, and liquid biopsies in the management of NSCLC
- To learn about the management of patients after progression, side effects of treatments and the use of targeted agents in NSCLC, and obtain some highlights of ongoing clinical research

---

## ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano, Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Wednesday, 22 May 2024

<b>09:00-09:10</b> 10'	<b>Opening and welcome</b>	
10'	Introduction and objectives	Pasi A. Jänne, US Solange Peters, CH
<b>09:10-10:05</b> 55'	<b>SESSION 1</b> <b>Screening, diagnosis, and staging</b>	<b>Chair:</b> <b>Solange Peters, CH</b>
20'	Early detection of lung cancer: Biology, screening and cost-effectiveness	Haseem Ashraf, NO
20'	The role of pathology and genetic/molecular analyses for primary cancer diagnostics	Patrick Micke, SE
15'	Q&A	All
<b>10:05-10:35</b>	<b>Coffee break</b>	
<b>10:35-11:15</b> 40'	<b>SESSION 2</b> <b>Adjuvant therapy</b>	<b>Chair:</b> <b>Pasi A. Jänne, US</b>
25'	Adjuvant and neo-adjuvant chemotherapy, radiotherapy targeted and immunotherapeutic agents: Clinical evidence and clinical research	Enriqueta Felip, ES
15'	Q&A	All
<b>11:15-11:55</b> 40'	<b>SESSION 3</b> <b>Multidisciplinary lung tumour board – Part I</b>	<b>Chair:</b> <b>Pasi A. Jänne, US</b>
40'	Management of stage III - Case presentation <ul style="list-style-type: none"> <li>- Surgeon's point of view</li> <li>- Radiotherapist's point of view</li> <li>- Medical oncologist's point of view</li> <li>- Discussion</li> </ul>	Inger Johanne Zwicky Eide, NO Åslaug Helland, NO Ilkka Ilonen, FI Jan Nyman, SE
<b>11:55-12:35</b> 40'	<b>SESSION 4</b> <b>Multidisciplinary lung tumour board – Part II</b>	<b>Chair:</b> <b>Solange Peters, CH</b>
40'	Management of oligometastatic disease - Case presentation <ul style="list-style-type: none"> <li>- Surgeon's point of view</li> <li>- Radiotherapist's point of view</li> <li>- Medical oncologist's point of view</li> <li>- Discussion</li> </ul>	Ilkka Ilonen, FI Karin Lindberg, SE Jens Benn Sørensen, DK
<b>12:35-13:35</b>	<b>Lunch</b>	
<b>13:35-14:35</b> 60'	<b>SESSION 5</b> <b>Audience cases</b>	<b>Chairs:</b> <b>Pasi A. Jänne, US</b> <b>Solange Peters, CH</b>
60'	Participants clinical case discussion (6x10')	Faculty
<b>14:35-15:05</b>	<b>Coffee break</b>	
<b>15:05-16:00</b> 55'	<b>SESSION 6</b> <b>Systemic therapy for advanced NSCLC</b>	<b>Chair:</b> <b>Pasi A. Jänne, US</b>
20'	Immune Checkpoint Inhibitors as a consolidation in stage III NSCLC	Åslaug Helland, NO
20'	Immune Checkpoint Inhibitors across lines of metastatic NSCLC	Solange Peters, CH
15'	Q&A	All
<b>20:00</b>	<b>Networking dinner</b>	

Thursday, 23 May 2024

<b>08:30-10:25</b> 115'	<b>SESSION 7</b> Targeted therapies	<b>Chair:</b> Solange Peters, CH
20'	Systemic therapy for non-oncogene addicted NSCLC, including ADC	Egbert F. Smit, NL
20'	New treatment options for EGFR-mutated NSCLC	Pasi A. Jänne, US
20'	New treatment options for ALK-ROS1 rearranged NSCLC	Alessandra Curioni-Fontecedro, CH
20'	KRAS mutant NSCLC	Odd Terje Brustugun, NO
20'	RET/TRK/BRAF/MET	Noemi Reguart, ES
15'	Q&A	All
<b>10:25-10:55</b>	<b>Coffee break</b>	
<b>10:55-11:25</b> 30'	<b>SESSION 8</b> Audience cases	<b>Chairs:</b> Pasi A. Jänne, US Solange Peters, CH
30'	Participants clinical case discussion (3x10')	Faculty
<b>11:25-13:00</b> 95'	<b>SESSION 9</b> Other thoracic tumours and molecular testing	<b>Chair:</b> Pasi A. Jänne, US
20'	Optimal platform and sequence for biomarker testing in advanced NSCLC: IHC, PCR, NGS and more	Keith M. Kerr, UK
20'	Liquid biopsy applications in the early detection and management of NSCLC patients	Odd Terje Brustugun, NO
20'	Immunotherapy for SCLC	Noemi Reguart, ES
20'	Immunotherapy for mesothelioma	Alessandra Curioni-Fontecedro, CH
15'	Q&A	All
<b>13:00-13:10</b> 10'	<b>Conclusion and take-home messages</b>	<b>Pasi A. Jänne, US</b> <b>Solange Peters, CH</b>
<b>13:10-14:10</b>	<b>Lunch</b>	

**Note:** Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion